Adagio - International Biopharmaceutical Industry

Current Edition

news

Adagio plans comeback for COVID drug, but is it too late?

Dive Brief: Adagio Therapeutics said it will ask the Food and Drug Administration for emergency authorization of its COVID-19 drug after announcing Wednesday that ...

1 April 2022 news Adagio | adintrevimab

Continue Reading →

news

Adagio pledges to press forward with COVID drug as CEO to resign

Dive Brief: Adagio Therapeutics CEO Tillman Gerngross has agreed "in principle" to resign as head of the COVID-19 drug developer amid confusion over whether its mo...

24 February 2022 news Adagio | Adimab

Continue Reading →

news

Adagio, after bold promises, says antibody drug won’t work well against omicron

The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with future outbreaks. The c...

16 December 2021 news Adagio | ADG20

Continue Reading →

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Current Edition

Upcoming Events

Advertisement

Adagio plans comeback for COVID drug, but is it too late?

Adagio pledges to press forward with COVID drug as CEO to resign

Adagio, after bold promises, says antibody drug won’t work well against omicron

International Biopharmaceutical Industry